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Coronavirus COVID-19 and Relevance 
for Dermatologists – Are We Ready for 
the Battle?
Carsten sauer Mikkelsen1,2, kristian Bakke arvesen2, 
luit Penninga3, and Peter Bjerring2
1Specialist in Dermato-venereology, Private Practice in Derma-
to-venereology, Brønderslev, Denmark, 2Specialist in Dermato-venereology, Research lab. Department of Dermato-venereology, 
Aalborg University Hospital, Denmark, and 3Specialist in Surgery, Ilulissat Hospital, Avannaa Region, Ilulissat, Greenland.
On December 31, 2019, the first registered case of “atypical ARDS/interstitial pneumonia” came from the 
Chinese city of Wuhan, Hubei. On February 11, 2020 the WHO officially announced the new name of the 
patho logy associated with the coronavirus: COVID-19 (Coronavirus Disease 2019) (1). It is a new strain of RNA 
virus that has not previously been identified in humans.
Cutaneous manifestation in patients with Corona 
CoViD-19
Data in the literature so far about skin manifestations in 
COVID-19 are very limited.
A group of dermatologists from Lecco in Italy collected data 
from 88 patients with COVID-19. Eighteen patients (20.4%) 
developed cutaneous manifestations. Eight patients devel-
oped cutaneous involvement at the onset, 10 patients only 
after hospitalization. The cutaneous manifestations seen 
were: erythematous rash (14 patients), widespread urticaria 
(3 patients), and chicken-pox like vesicles (1 patient). The 
skin on the trunk was the main involved region. Itching was 
insignificant or absent and usually lesions 
healed in few days. Apparently, there was 
no correlation between skin symptoms 
and disease severity. It was concluded that 
skin manifestations related to COVID-19 
infection are similar to those occurring 
during common viral infections (1).
A case report from Thailand presented a 
patient with a skin rash with petechiae. 
Because dengue is very common in Thai-
land and the patient also had low platelet 
count, a clinical diagnosis of dengue was made by the first 
physician in-charge. In this case, the patient further presented 
respiratory problems and was referred to the tertiary medical 
centre. Other common virus infections that might cause fever, 
rash and respiratory problem were ruled out by laboratory 
investigation and the final diagnosis of COVID-19 infection 
was confirmed by RT-PCR (6). The group concluded it is a pos-
sibility that a COVID-19 patient might initially present with 
a skin rash which can be misdiagnosed as another common 
disease. Additionally, some of these COVID-19 patients are 
afebrile initially (3). 
More case reports from China present COVID-19 patients with 
urticaria as a clinical cutaneous manifestation (7).
Another study from Wuhan registered the clinical character-
istics of 140 community-infected patients with COVID-19. It 
was found that the median age of all patients were 57 years 
old with almost 1:1 male:female ratio. Fever (91.7 %), cough 
(75.0%) and fatigue (75%), were the most common symptoms 
in COVID-19 patients. More than 1/3 of the patients had chest 
tightness or dyspnoea and gastrointestinal symptoms (nausea, 
diarrhoea, and anorexia). CT scans or 
X-ray showed bilateral ground-glass and 
patchy opacity in 89.6% of the patients. 
No asthmatic patients were identified in 
this report, and only a few patients had 
self-reported drug hypersensitivity and 
urticaria. Other allergies such as allergic 
rhinitis, atopic dermatitis, and food aller-
gy were not reported (8).
A retrospective study found 7 critical 
COVID-19 patients with acro-ischaemia 
in a single centre in Wuhan. All patients had acro-ischaemia 
presentations including finger/toe cyanosis, skin bullae and 
dry gangrene. D-dimer, fibrinogen and fibrinogen degra-
dation product (FDP) were significantly elevated in most 
patients. Prothrombin time (PT) were prolonged in 4 pa-
tients. D-dimer and FDP levels increased progressively when 
COVID-19 exacerbated, and 4 patients were diagnosed with 
definite disseminated intravascular coagulation (DIC). Six 
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patients received low molecular weight heparin (LMWH) 
treatment, after which their D-dimer and FDP decreased, but 
there was no significant improvement in clinical symptoms. 
Five patients died finally and the median time from acro- 
ischaemia to death was 12 days. It was concluded that hyper-
coagulation status in critical COVID-19 patients should be 
monitored closely, and that anticoagulation therapy should 
be considered in selected patients (9).
Conclusion
The data from studies concerning cutaneous manifestations in 
patients with COVID-19 varies a lot. Nevertheless, dermatolo-
gists should recognize the possibility that COVID-19 patients 
might present with only a skin rash initially, and should think 
of the possibility of the patient having Corona COVID-19 in 
order to prevent further transmission. 
Cutaneous manifestation in healthCare workers 
fighting Corona CoViD-19
In a study from China the skin damage among healthcare 
workers (HCW) managing corona virus COVID-19 was reg-
istered. The general prevalence of skin damages caused by 
enhanced infection-prevention measures was 97.0% among 
first-line HCW. The affected sites included nasal bridge, hands, 
cheek and forehead, and nasal bridge was the most common-
ly affected (83.1%). Among a series of symptoms and signs, 
dryness/tightness and desquamation were the most common 
symptom (70.3%) and sign (61.6%). The HCW who wore some 
medical devices longer than 6 h had higher risks of skin dam-
ages than those who did less time. The more frequent (>10 
times/day) hand hygiene and longer time of gloves wearing 
could increase the risk of skin damages of the hands. 
In conclusion, the study demonstrated that the prevalence 
of skin damages of first-line HCW was very high. Moreover, 
longer exposure time was a significant risk factor which 
highlights that the working time of first-line staff should be 
arranged reasonably. Besides, prophylactic dressings could be 
considered to alleviate device-related pressure injuries (10). 
The above information has been highlighted in a letter from 
AAD and suggestions for prevention are given for healthcare 
workers (HCW). HCWs fighting COVID-19 are prone to dam-
age of both skin and mucosa barriers. In order to minimize 
skin and mucosa barrier breakdown, HCWs should adhere 
to standards on wearing protective equipment and avoid 
over-protection. At the same time, measures of skin care are 
recommended during work. AAD also provides professional 
advice on prevention and management of mild skin disorders. 
Nevertheless, timely referral to dermatologists is necessary if 
dermatoses are sustained or worsened gradually (11,12).
patients with Corona CoViD-19 skin Diseases anD 
immunosuppressiVe treatment
The British Association of Dermatologists (BAD) has addressed 
potential issues regarding COVID-19 infection of patients 
who are taking medicines that affect the immune system 
such as biologic therapies and/or immunosuppressants (13). 
BAD inform patients taking a medication that targets their 
immune system that COVID-19 infection may pose a higher 
risk and therefore specific measures are advised. There are 
two categories of measures: shielding and very careful social 
distancing. Shielding is a measure to protect people who are 
at very high risk of severe illness if contracting (COVID-19) 
infection by minimising all face to face interaction between 
those who are extremely vulnerable and others. Shielding is a 
step up from very careful social distancing. People advised not 
leave their home for 12 weeks (current estimate until late June 
2020). Asking people to stay at home and avoid contact is an 
intensified form of social distancing. For people taking drugs 
that target the immune system, very careful social distancing 
is advised by BAD. 
Which category that applies to an actual patient depends on 
the medicine(s), age and what other medical problems the 
patient may have. The patient will be advised by the doctors 
prescribing their immune modulating drugs whether they 
are considered an ‘extremely vulnerable’ person needing to 
shield. BAD do not advise patients to stop their medicine with-
out prior discussion with their dermatologist since stopping 
treatment could worsen their skin condition resulting in need 
for hospital treatment. Self-isolation applies if the patients 
have symptoms of COVID-19 infection or if the patient lives 
with someone who has symptoms. In this case they may NOT 
leave the house for 7–14 days. Many out-patient services are 
arranging for patients to be reviewed by telephone or online. 
The hospital departments contact patients to confirm these 
arrangements. Review and frequency of routine blood tests 
may become less often during this time but hospitals have 
made arrangements for easy access to bloods tests in their 
departments on a daily basis.
Patients on biologics will continue to receive their biologics 
via homecare delivery companies. BAD are not aware of 
any current stock- or delivery issues. Each hospital and GP 
practice will make its own arrangements for arranging repeat 
prescriptions.
BAD advice that dermatologists should only be starting or 
continuing patients on isotretinoin where the risks are out-
weighed by the benefits. This needs to be considered carefully 
in light of the need to reduce face-to-face consultations in the 
current pandemic, and the uncertainty of reliable follow-up/
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monitoring over the coming months. Monitoring of side 
effects and blood monitoring, will need to be carried out as 
usual with remote consultations.
Skin cancer services should be attenuated to ensure that 
the following guidance is implemented according to BAD: 
Consider cancelling all elective surgeries. Consider deferring 
all surgical excisions of BCC, including Mohs micrographic 
surgery, for 3–6 months, with exceptions for highly-symp-
tomatic lesions. Highly symptomatic lesions and those with 
potential for significant rapid growth could be considered for 
surgery. Consider deferring surgical excisions of squamous cell 
carcinomas (SCC), such as SCC in situ and small, well differen-
tiated SCCs. Prioritise the following lesions: Rapidly-enlarging 
tumours, poorly-differentiated tumours, perineural tumours, 
ulcerated and symptomatic lesions; lesions in patients with 
significant risk factors (while balancing the risk of COVID-19 
complications for these high-risk patients). Consider deferring 
treatment of melanoma in situ for 2–3 months.
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